Jinmin Han1,2, Chengrui Fu2,3, Baosheng Li4. 1. Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China. 2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China. 3. Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. 4. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China. bsli@sdfmu.edu.cn.
Abstract
OBJECTIVE: The purpose of this study was to assess whether thoracic radiotherapy (TRT) combined with chemotherapy (CHT) showed promising anti-tumour activity in extensive-stage small cell lung cancer (ES-SCLC), to explore practice patterns for the radiation time and dose/fractionation and to identify prognostic factors for patients who would benefit from CHT/TRT. METHODS: A total of 492 ES-SCLC patients were included from January 2010 to March 2019, 244 of whom received CHT/TRT. Propensity score matching was performed to minimize bias between the CHT/TRT and CHT-alone groups. Patients in the CHT/TRT group were categorized into four subgroups based on the number of induction CHT cycles. For effective dose fractionation calculations, we introduced the time-adjusted biological effective dose (tBED). Categorical variables were analysed with chi-square tests and Fisher's exact tests. Kaplan-Meier curves were generated to estimate survival rates using the R-project. Multivariate prognostic analysis was performed with Cox proportional hazards models. RESULTS: Patients who received CHT/TRT experienced improved overall survival (OS) (18.1 vs 10.8 months), progression-free survival (PFS) (9.3 vs 6.0 months) and local recurrence-free survival (LRFS) (12.0 vs 6.6 months) before matching, with similar results after matching. In the CHT/TRT group, the median LRFS times for the groups based on the radiation time were 12.7, 12.0, 12.0, and 9.0 months, respectively. Early TRT had a tendency to prolong PFS (median 10.6 vs 9.8 vs 9.0 vs 7.7 months, respectively, p = 0.091) but not OS (median 17.6 vs 19.5 vs 17.2 vs 19.0 months, respectively, p = 0.622). Notably, patients who received TRT within 6 cycles of CHT experienced prolonged LRFS (p = 0.001). Regarding the radiation dose, patients in the high-dose group (tBED > 50 Gy) who achieved complete response and partial response (CR and PR) to systemic therapy had relatively short OS (median 27.1 vs 22.7, p = 0.026) and PFS (median 11.4 vs 11.2, p = 0.032), but the abovementioned results were not obtained after the exclusion of patients who received hyperfractionated radiotherapy (all p > 0.05). CONCLUSION: CHT/TRT could improve survival for ES-SCLC patients. TRT performed within 6 cycles of CHT and hyperfractionated radiotherapy (45 Gy in 30 fractions) may be a feasible treatment scheme for ES-SCLC patients.
OBJECTIVE: The purpose of this study was to assess whether thoracic radiotherapy (TRT) combined with chemotherapy (CHT) showed promising anti-tumour activity in extensive-stage small cell lung cancer (ES-SCLC), to explore practice patterns for the radiation time and dose/fractionation and to identify prognostic factors for patients who would benefit from CHT/TRT. METHODS: A total of 492 ES-SCLCpatients were included from January 2010 to March 2019, 244 of whom received CHT/TRT. Propensity score matching was performed to minimize bias between the CHT/TRT and CHT-alone groups. Patients in the CHT/TRT group were categorized into four subgroups based on the number of induction CHT cycles. For effective dose fractionation calculations, we introduced the time-adjusted biological effective dose (tBED). Categorical variables were analysed with chi-square tests and Fisher's exact tests. Kaplan-Meier curves were generated to estimate survival rates using the R-project. Multivariate prognostic analysis was performed with Cox proportional hazards models. RESULTS:Patients who received CHT/TRT experienced improved overall survival (OS) (18.1 vs 10.8 months), progression-free survival (PFS) (9.3 vs 6.0 months) and local recurrence-free survival (LRFS) (12.0 vs 6.6 months) before matching, with similar results after matching. In the CHT/TRT group, the median LRFS times for the groups based on the radiation time were 12.7, 12.0, 12.0, and 9.0 months, respectively. Early TRT had a tendency to prolong PFS (median 10.6 vs 9.8 vs 9.0 vs 7.7 months, respectively, p = 0.091) but not OS (median 17.6 vs 19.5 vs 17.2 vs 19.0 months, respectively, p = 0.622). Notably, patients who received TRT within 6 cycles of CHT experienced prolonged LRFS (p = 0.001). Regarding the radiation dose, patients in the high-dose group (tBED > 50 Gy) who achieved complete response and partial response (CR and PR) to systemic therapy had relatively short OS (median 27.1 vs 22.7, p = 0.026) and PFS (median 11.4 vs 11.2, p = 0.032), but the abovementioned results were not obtained after the exclusion of patients who received hyperfractionated radiotherapy (all p > 0.05). CONCLUSION:CHT/TRT could improve survival for ES-SCLCpatients. TRT performed within 6 cycles of CHT and hyperfractionated radiotherapy (45 Gy in 30 fractions) may be a feasible treatment scheme for ES-SCLCpatients.
Authors: Ben J Slotman; Harm van Tinteren; John O Praag; Joost L Knegjens; Sherif Y El Sharouni; Matthew Hatton; Astrid Keijser; Corinne Faivre-Finn; Suresh Senan Journal: Lancet Date: 2015-04-04 Impact factor: 79.321
Authors: Ben J Slotman; Corinne Faivre-Finn; Harm van Tinteren; Astrid Keijser; John Praag; Joost Knegjens; Matthew Hatton; Iris van Dam; Annija van der Leest; Bart Reymen; Jos Stigt; Kate Haslett; Devashish Tripathi; Egbert F Smit; Suresh Senan Journal: Lung Cancer Date: 2017-03-21 Impact factor: 5.705
Authors: Ben J Slotman; Harm van Tinteren; John O Praag; Joost L Knegjens; Sherif Y El Sharouni; Matthew Hatton; Astrid Keijser; Corinne Faivre-Finn; Suresh Senan Journal: Lancet Date: 2014-09-14 Impact factor: 79.321
Authors: Charles M Rudin; Nofisat Ismaila; Christine L Hann; Narinder Malhotra; Benjamin Movsas; Kim Norris; M Catherine Pietanza; Suresh S Ramalingam; Andrew T Turrisi; Giuseppe Giaccone Journal: J Clin Oncol Date: 2015-09-08 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Qunzhou Zhang; Xudong Tang; Zuo-Feng Zhang; Rita Velikina; Shihong Shi; Anh D Le Journal: Clin Cancer Res Date: 2007-08-15 Impact factor: 12.531
Authors: Hari Menon; Rishab Ramapriyan; Taylor R Cushman; Vivek Verma; Hans H Kim; Jonathan E Schoenhals; Cemre Atalar; Ugur Selek; Stephen G Chun; Joe Y Chang; Hampartsoum B Barsoumian; Quynh-Nhu Nguyen; Mehmet Altan; Maria A Cortez; Stephen M Hahn; James W Welsh Journal: Front Immunol Date: 2019-02-15 Impact factor: 7.561
Authors: A S Mansfield; A Każarnowicz; N Karaseva; A Sánchez; R De Boer; Z Andric; M Reck; S Atagi; J-S Lee; M Garassino; S V Liu; L Horn; X Wen; C Quach; W Yu; F Kabbinavar; S Lam; S Morris; R Califano Journal: Ann Oncol Date: 2019-12-09 Impact factor: 32.976